DORIS HASTEY: Open Payments
NPI 1790201820 · MENA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$818 in 60 payments from 8 companies in 2025. Trend: 2023 $502 · 2024 $407 · 2025 $818
Food & beverage: $818
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $397 |
| Otsuka America Pharmaceutical, Inc. | 15 | $156 |
| Alkermes, Inc. | 3 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Exact Sciences Corporation | 1 | $15 |
Products named: VRAYLAR, REXULTI, ARISTADA, QULIPTA, CAPLYTA, Qelbree, UBRELVY, JOURNAVX.
Industry payments across AR — which companies pay providers there.
